Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fibrovein Holdings is a private UK healthcare and specialty pharmaceutical company associated with the commercial management of Fibrovein, a sodium tetradecyl sulfate sclerosant used for the treatment of varicose veins. The business appears to operate from Hereford, United Kingdom, and is tied to the longstanding Fibrovein brand and related pharmaceutical activities. Fibrovein is a sterile injectable detergent sclerosant that has been marketed for decades and is manufactured under cGMP conditions. The company looks to be commercially focused rather than a research-stage biotech, with activity centered on distribution, product stewardship, and related medical product services rather than a broad clinical development pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Fibrovein Holdings.